Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)

The Phase II NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with cisplatin based neoadjuvant chemotherapy in a clinical practice setting.

Trial Details

NCT ID
NCT06960577
Phase
PHASE2
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Bladder Cancer
Interventions
  • Durvalumab
  • Methotrexate
  • Vinblastine
  • Doxorubicin
  • Cisplatin
  • Gemcitabine
Locations (sample)
  • Chermside, Australia|-27.38472,153.03062
  • Elizabeth Vale, Australia|-34.74857,138.66819
  • Heidelberg, Australia|-37.75,145.06667
  • Hong Kong, Australia
  • Kogarah, Australia|-33.9681,151.13564

Key Eligibility Criteria

  • Participants with clinical tumour stage T2-T4aN0/1M0 or T1N1M0 with transitional or mixed transitional cell histology
  • Participants must be planning to undergo radical cystectomy
  • Participants who have not received prior systemic chemotherapy or immunotherapy for treatment of muscle-invasive bladder cancer
  • ECOG performance status of 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Bladder Cancer Trials on Trialify →